female contraceptive agents

Summary

Summary: Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading.

Top Publications

  1. ncbi Bleeding problems and progestogen-only contraception
    Charlotte Porter
    Victoria Clinic, Nottingham, UK
    J Fam Plann Reprod Health Care 28:178-81. 2002
  2. ncbi Advances in hormonal contraception
    Nupur Gupta
    Tufts University School of Medicine, Boston, MA 02111, USA
    Adolesc Med Clin 17:653-71; abstract xi. 2006
  3. pmc Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093
    D Heather Watts
    National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892, USA
    Contraception 77:84-90. 2008
  4. ncbi Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study
    Ludo Lavreys
    Departments of Epidemiology and Medicine, University of Washington, Seattle, WA, USA
    AIDS 18:695-7. 2004
  5. ncbi Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents
    Young A Han
    Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Weill Medical College of Cornell University, 515 East 71st Street, S 412, New York, NY 10021, USA
    Contraception 76:132-8. 2007
  6. ncbi Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women
    Jared M Baeten
    Seattle HIV Prevention Trials Unit, Department of Medicine, University of Washington, 9012 Boren Avenue, Seattle, WA 98104, USA
    AIDS 21:1771-7. 2007
  7. ncbi Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort
    Immo Kleinschmidt
    London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
    Contraception 75:461-7. 2007
  8. ncbi Endometrial effects of intrauterine levonorgestrel
    Anja Guttinger
    Division of Reproductive and Developmental Sciences, The Queen s Medical Research Institute, Centre for Reproductive Biology, The University of Edinburgh, EH16 4TJ Edinburgh, UK
    Contraception 75:S93-8. 2007
  9. ncbi Prospective clinical trials designed to assess the use of hormonal contraceptives and risk of HIV acquisition
    Charles S Morrison
    Family Health International, Research Triangle Park, NC, USA
    J Acquir Immune Defic Syndr 38:S17-8. 2005
  10. pmc Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women
    Barbra A Richardson
    Department of Biostatistics, University of Washington, Seattle, WA 98194 2499, USA
    AIDS 21:749-53. 2007

Detail Information

Publications186 found, 100 shown here

  1. ncbi Bleeding problems and progestogen-only contraception
    Charlotte Porter
    Victoria Clinic, Nottingham, UK
    J Fam Plann Reprod Health Care 28:178-81. 2002
  2. ncbi Advances in hormonal contraception
    Nupur Gupta
    Tufts University School of Medicine, Boston, MA 02111, USA
    Adolesc Med Clin 17:653-71; abstract xi. 2006
    ..The article provides a short description of each of these contraceptive methods, information about compliance, side effects, and efficacy, and an update on that particular method...
  3. pmc Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093
    D Heather Watts
    National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892, USA
    Contraception 77:84-90. 2008
    ..We evaluated the safety and tolerability of depot medroxyprogesterone acetate (DMPA) among women on ARV...
  4. ncbi Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study
    Ludo Lavreys
    Departments of Epidemiology and Medicine, University of Washington, Seattle, WA, USA
    AIDS 18:695-7. 2004
  5. ncbi Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents
    Young A Han
    Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Weill Medical College of Cornell University, 515 East 71st Street, S 412, New York, NY 10021, USA
    Contraception 76:132-8. 2007
    ..Construction of vaginal rings to deliver nonhormonal contraceptives and 3'-azido-3'-deoxythymidine (AZT) as an anti-HIV agent and determination of their daily release and efficacy in vitro...
  6. ncbi Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women
    Jared M Baeten
    Seattle HIV Prevention Trials Unit, Department of Medicine, University of Washington, 9012 Boren Avenue, Seattle, WA 98104, USA
    AIDS 21:1771-7. 2007
    ..A recent study from Uganda and Zimbabwe found that women using hormonal contraception were at increased risk for HIV-1 if they were seronegative for herpes simplex virus type 2 (HSV-2), but not if they were HSV-2 seropositive...
  7. ncbi Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort
    Immo Kleinschmidt
    London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
    Contraception 75:461-7. 2007
    ....
  8. ncbi Endometrial effects of intrauterine levonorgestrel
    Anja Guttinger
    Division of Reproductive and Developmental Sciences, The Queen s Medical Research Institute, Centre for Reproductive Biology, The University of Edinburgh, EH16 4TJ Edinburgh, UK
    Contraception 75:S93-8. 2007
    ..Much remains to be determined about the mechanisms involved in suppression of menstruation, BTB episodes and the local endometrial environment with local LNG administration...
  9. ncbi Prospective clinical trials designed to assess the use of hormonal contraceptives and risk of HIV acquisition
    Charles S Morrison
    Family Health International, Research Triangle Park, NC, USA
    J Acquir Immune Defic Syndr 38:S17-8. 2005
  10. pmc Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women
    Barbra A Richardson
    Department of Biostatistics, University of Washington, Seattle, WA 98194 2499, USA
    AIDS 21:749-53. 2007
    ..To assess the immediate and longer-term effects of the use of hormonal contraception on the progression of HIV-1 disease in postpartum women...
  11. ncbi The long-term actions of etonogestrel and levonorgestrel on decidualized and non-decidualized endometrium in a mouse model mimic some effects of progestogen-only contraceptives in women
    Naomi B Morison
    Prince Henry s Institute, PO Box 5152, Clayton, Victoria, Australia
    Reproduction 133:309-21. 2007
    ..MMP7 was primarily associated with tissue repair. Therefore, this model mimics some of the changes observed in endometria of women using p-only contraceptives and provides an opportunity for functional studies...
  12. ncbi Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia
    Robert W Shaw
    Academic Division of Obstetrics and Gynaecology, University of Nottingham, Derby, UK
    Aust N Z J Obstet Gynaecol 47:335-40. 2007
    ....
  13. ncbi The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women--effects on bleeding patterns, ovarian function and genital shedding of HIV
    Oskari Heikinheimo
    Department of Obstetrics and Gynaecology, University of Helsinki, Finland
    Hum Reprod 21:2857-61. 2006
    ..The levonorgestrel-releasing intrauterine system (LNG-IUS) is a highly effective contraceptive with additional health benefits. The objective of this study was to evaluate the effects of the LNG-IUS among HIV-infected women...
  14. ncbi The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera
    L Bahamondes
    Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas, UNICAMP, Campinas, Brazil
    Contraception 62:23-7. 2000
    ..In conclusion, the use of Depo-Provera between two and three years did not affect vaginal thinning of the epithelium, Langerhans cell count or maturation index...
  15. ncbi Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding
    M Hickey
    Department of Reproductive Science and Medicine, Imperial College School of Medicine at St Mary s, Norfolk Place W2 1PG, London, UK
    Hum Reprod 15:1509-14. 2000
    ..83, P = 0.01). There was no obvious relationship between subepithelial bleeding and circulating concentrations of oestradiol and progesterone...
  16. ncbi A longitudinal study of changes in endometrial microvascular density in Norplant implant users
    M Hickey
    Sydney Centre for Reproductive Health Research, Department of Obstetrics and Gynaecology, University of Sydney, Australia
    Contraception 59:123-9. 1999
    ..The findings suggest that the endometrial vasculature is profoundly altered in the early months of Norplant implant exposure when bleeding problems are most common...
  17. ncbi Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model
    P G L Lalitkumar
    Division of Obstetrics and Gynecology, Department of Woman and Child Health, Karolinska Institutet, Karolinska University Hospital, S 171 76, Stockholm, Sweden
    Hum Reprod 22:3031-7. 2007
    ..This study investigates the effect of levonorgestrel and mifepristone on attachment of human embryos to an in vitro endometrial construct...
  18. ncbi Spinal bone density in women using depot medroxyprogesterone contraception
    T Cundy
    Department of Medicine, The Faculty of Medicine and Health Sciences, University of Auckland, New Zealand
    Obstet Gynecol 92:569-73. 1998
    ..To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot medroxyprogesterone acetate...
  19. ncbi Health status function after treatment with thermal balloon endometrial ablation and levonorgestrel intrauterine system for idiopathic menorrhagia: a randomized study
    Wing Hung Tam
    Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, SAR, China
    Gynecol Obstet Invest 62:84-8. 2006
    ..To compare patients' health status function after treatment with thermal balloon endometrial ablation (TBEA) and levonorgestrel intrauterine system (LNG-IUS) for idiopathic menorrhagia...
  20. ncbi Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda
    Mohammed Kiddugavu
    Rakai Project, Uganda Virus Research Institute, Entebbe, Uganda
    AIDS 17:233-40. 2003
    ..Hormonal contraceptives have been associated with increased risk of HIV acquisition...
  21. ncbi Endometrial vessel maturation in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time
    Ravet Stéphanie
    Laboratory of Tumor and Development Biology, Center of Experimental Cancer Research, University de Liège, Tour de Pathologie B23, Avenue de l Hopital, GIGA R, Sart Tilman, B 4000 Liege, Belgium
    Hum Reprod 22:3084-91. 2007
    ..The area, density and maturation of endometrial vessels were quantified in 19 endometrial biopsies of women with LNG-IUS and in 10 normally ovulating patients during mid-luteal phase...
  22. ncbi Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women
    Päivi Lehtovirta
    Department of Obstetrics and Gynecology, University of Helsinki, SF 00029 Helsinki, Finland
    Contraception 75:37-9. 2007
    ..Yet, little is known about LNG-IUS use in HIV-infected women...
  23. ncbi Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery
    R L Jones
    Prince Henry s Institute of Medical Research, Clayton, Victoria, Australia
    Hum Reprod 15:162-72. 2000
    ....
  24. ncbi Perivascular smooth muscle alpha-actin is reduced in the endometrium of women with progestin-only contraceptive breakthrough bleeding
    P A Rogers
    Monash University Department of Obstetrics and Gynaecology, Monash Medical Centre, Victoria, Australia
    Hum Reprod 15:78-84. 2000
    ....
  25. ncbi Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study
    J M Baeten
    Department of Epidemiology, University of Washington, Seattle, WA 98104 2499, USA
    Am J Obstet Gynecol 185:380-5. 2001
    ..To examine the relationship between use of oral contraceptive pills or depot medroxyprogesterone acetate and sexually transmitted disease acquisition...
  26. ncbi Effects of thrombin, hypoxia, and steroids on interleukin-8 expression in decidualized human endometrial stromal cells: implications for long-term progestin-only contraceptive-induced bleeding
    Charles J Lockwood
    Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Clin Endocrinol Metab 89:1467-75. 2004
    ..However, LTPOC-induced hypoxia and excess thrombin generation enhance IL-8 expression in decidualized HESCs, thereby eliciting aberrant angiogenesis and inflammation that promote the onset of abnormal uterine bleeding...
  27. ncbi Relationship between progesterone receptor level in endometrium and bleeding pattern in depot medroxyprogesterone acetate users
    Pichai Chotnopparatpattara
    Department of Obstetrics and Gynaecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
    J Med Assoc Thai 86:172-7. 2003
    ..05). In conclusion, after a second dose of DMPA, subjects with amenorrhea had a higher stromal PR score than those with uterine bleeding...
  28. ncbi The Mirena levonorgestrel system
    C Jay McGavigan
    Department of Obstetrics and Gynecology, Southern General Hospital, South Glasgow University Hospitals NHS Trust, Govan, Glasgow, UK
    Drugs Today (Barc) 39:973-84. 2003
    ..Detailed counseling is crucial to explain this anticipated side effect in order to reduce unnecessary discontinuation of treatment...
  29. ncbi Recent developments in hormone delivery systems
    Lee P Shulman
    Department of Obstetrics and Gynecology, Feinberg School of Medicine at Northwestern University, Chicago, IL 60611, USA
    Am J Obstet Gynecol 190:S39-48. 2004
    ..Finally, hormonal implants that release low doses of progestins have been used for more than 30 years by a total of 10 million women, and easier-to-use implants will soon be available...
  30. ncbi Pregnancy in effectiveness trials of HIV prevention agents
    Elizabeth G Raymond
    Family Health International, Research Triangle Park, North Carolina, USA
    Sex Transm Dis 34:1035-9. 2007
  31. ncbi A three-dimensional study of endometrial microvessels in women using the contraceptive subdermal levonorgestrel implant system, norplant
    M Simbar
    Department of Obstetrics and Gynaecology, Queen Elizabeth II Research Institute for Mothers and Infants, The University of Sydney, Sydney, NSW, 2006, Australia
    Micron 35:589-95. 2004
    ....
  32. ncbi The role of tissue factor in regulating endometrial haemostasis: implications for progestin-only contraception
    C J Lockwood
    Department of Obstetrics and Gynecology, New York University School of Medicine, NY 10016, USA
    Hum Reprod 15:144-51. 2000
    ....
  33. ncbi Abnormal uterine bleeding associated with hormonal contraception
    Sarina Schrager
    Department of Family Medicine, University of Wisconsin Medical School, Madison 53715, USA
    Am Fam Physician 65:2073-80. 2002
    ....
  34. doi Hormonal contraception and HIV prevalence in four African countries
    Pauline M Leclerc
    Epidemiologie des Maladies Emergentes, Institut Pasteur, 25 rue du Docteur Roux, Paris, France
    Contraception 77:371-6. 2008
    ..The HIV seroprevalence among women aged 15-24 years was compared according to their pattern of contraceptive use in four African countries: Kenya, Lesotho, Malawi and Zimbabwe...
  35. ncbi Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: an overview
    Jeffrey T Jensen
    Department of Obstetrics and Gynecology, UHN 70, Oregon Health and Science University, 3181 Sam Jackson Park Road, Portland, OR 97239, USA
    Obstet Gynecol Surv 60:604-12. 2005
    ....
  36. ncbi Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls
    Barbara A Cromer
    Department of Pediatrics, MetroHealth Medical Center, Cleveland, OH 44109, USA
    J Adolesc Health 35:434-41. 2004
    ....
  37. ncbi Benefit-risk assessment of the levonorgestrel intrauterine system in contraception
    Tiina Backman
    Department of Obstetrics and Gynecology, Turku University Hospital, Turku, Finland
    Drug Saf 27:1185-204. 2004
    ..Thus, the benefits of the levonorgestrel-releasing IUS make it a very suitable method of contraception for most women...
  38. ncbi Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK
    Susan J Varney
    CATALYST Health Economics Consultants, Northwood, Middlesex, UK
    Pharmacoeconomics 22:1141-51. 2004
    ....
  39. ncbi Expression of vascular endothelial growth factors and their receptors in human endometrium from women experiencing abnormal bleeding patterns after prolonged use of a levonorgestrel-releasing intrauterine system
    Bjorn Moller
    Department of Women s and Children s Health, Uppsala University, Sweden
    Hum Reprod 20:1410-7. 2005
    ..The aim of the study was to elucidate the possible association of these VEGF and receptors with bleeding disturbances among users of LNG-IUS...
  40. ncbi What's new in adolescent contraception: what residents and teachers need to know
    Eduardo Lara-Torre
    Kaza Medical Group, Milford, Delaware 19963, USA
    J Pediatr Adolesc Gynecol 18:133-5. 2005
  41. ncbi Effect of Norplant contraceptive on the bones of Nigerian women as assessed by quantitative ultrasound and serum markers of bone turnover
    Dorothy J Vanderjagt
    Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine, Albuquerque, NM 87131 0001, USA
    Contraception 72:212-6. 2005
    ..001). We conclude that although levonorgestrel contraceptive decreased overall bone turnover, it had no deleterious effect on the bone quality of women using Norplant implants for up to 4 years...
  42. ncbi Five years' experience with a small intracervical/intrauterine levonorgestrel-releasing device
    Paivi Pakarinen
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, 00029 HUS Helsinki, Finland
    Contraception 72:342-5. 2005
    ..A randomized study was performed to compare the efficacy, safety and acceptability of a new model of an intracervical/intrauterine contraceptive device (ICD) releasing 20 microg of levonorgestrel (LNG) per day...
  43. ncbi A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants
    Luis Bahamondes
    Human Reproduction Unit, Department of Obstetrics and Gynaecology, School of Medicine, Universidade Estadual de Campinas UNICAMP, 13084 971, Campinas, SP, Brazil
    Hum Reprod 21:466-70. 2006
    ..The aim of the study was to compare bone mineral density (BMD) before insertion and at 18 months of use of etonorgestrel- and levonorgestrel-releasing contraceptive implants...
  44. ncbi Effective use of hormonal contraceptives: Part II: Combined hormonal injectables, progestogen-only injectables and contraceptive implants
    Camaryn E Chrisman
    Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Contraception 73:125-33. 2006
    ..Norplant implants left in place for up to seven completed years remained effective among women who weighed <70 kg at the time of implant insertion, but their effectiveness decreased among women weighing >or=70 kg...
  45. ncbi Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia
    A Kriplani
    Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
    Int J Gynaecol Obstet 97:190-4. 2007
    ..To evaluate the efficacy, acceptability, and possible side effects of a levonorgestrel-releasing intrauterine system for menorrhagia...
  46. ncbi [Acceptability of intrauterine levonorgestrel delivery system (Mirena 52mg) after estrogen-progesterone oral contraception: results of a prospective multicentric study of 211 patients aged 25-35 years]
    P Collinet
    clinique de gynécologie, Hopital Jeanne de Flandre, CHRU de Lille, 2, Avenue Oscar Lambret, 59037 Lille Cedex
    J Gynecol Obstet Biol Reprod (Paris) 35:778-84. 2006
    ..The purpose of this study was to evaluate patient satisfaction among young women during the first year of use of the intrauterine hormonal system...
  47. ncbi Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas
    Takeshi Maruo
    Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, 650 0017, Japan
    Contraception 75:S99-103. 2007
    ..The cell type-specific action of CDB2914 on leiomyoma cells, without affecting the surrounding normal myometrial cells, is meaningful for understanding the usefulness of CDB2914 in the medical treatment of uterine myomas...
  48. ncbi Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosis
    Moamar Al-Jefout
    Department of Obstetrics and Gynaecology, Queen Elizabeth II Research Institute for Mothers and Infants, University of Sydney, New South Wales, Australia
    Aust N Z J Obstet Gynaecol 47:247-9. 2007
    ....
  49. ncbi Alternatives to oral regimens of contraception
    M Simon
    Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Minerva Ginecol 59:271-86. 2007
    ....
  50. ncbi Revisiting the intrauterine contraceptive device in adolescents
    Alina Toma
    Department of Obstetrics and Gynaecology, Queen s University, Kingston, Ontario, Canada
    J Pediatr Adolesc Gynecol 19:291-6. 2006
    ....
  51. ncbi Managing drug-resistant essential menorrhagia without hysterectomy
    Ritva Hurskainen
    Department of Obstetrics and Gynecology, Hyvinkaa Hospital, Hospital District of Helsinki and Uusimaa, Sairaalank 1, 05850 Hyvinkaa, Finland
    Best Pract Res Clin Obstet Gynaecol 20:681-94. 2006
    ..However, second generation ablation techniques may offer better cost-effectiveness than the first generation techniques, but the evidence is insufficient...
  52. ncbi Hormonal contraception: recent advances
    Anne Szarewski
    Margaret Pyke Centre, London
    J Fam Health Care 16:35-6. 2006
  53. ncbi Hormonal contraception and false-positive cervical cytology: is there an association?
    Anna V Hoekstra
    Department of Obstetrics and Gynecology, Illinois Masonic Medical Center, Chicago, USA
    J Low Genit Tract Dis 10:102-6. 2006
    ..The aim of the study was to determine if use of hormonal contraception influences the false-positive rate of cervical cytology when compared with loop electrosurgical excision procedure or cervical biopsy specimens...
  54. ncbi Levonorgestrel-releasing intrauterine system vs. transcervical endometrial resection for dysfunctional uterine bleeding
    B Gupta
    Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
    Int J Gynaecol Obstet 95:261-6. 2006
    ..To compare the acceptability, efficacy, adverse effects, and user satisfaction of a levonorgestrel intrauterine system (LNG-IUS) and transcervical resection of the endometrium (TCRE) for the treatment of dysfunctional uterine bleeding...
  55. ncbi [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil]
    Daniela Angerame Yela
    Departamento de Obstetricia e Ginecologia, Faculdade de Medicina, Universidade Estadual de Campinas UNICAMP, Campinas, Brazil
    Rev Assoc Med Bras 52:32-6. 2006
    ....
  56. ncbi Weight changes in clients on hormonal contraceptives in Zaria, Nigeria
    Saadatu Sule
    Department of Obstetrics and Gynaecology, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria
    Afr J Reprod Health 9:92-100. 2005
    ..This information will be beneficial in contraceptive counselling for clients in this environment and provide a baseline for further research...
  57. ncbi The effect of the levonorgestrel intrauterine system on uterine artery blood flow 1 year after insertion
    A Haberal
    Department of Gynecology, S S K Ankara Maternity and Women s Health Teaching Hospital, Ankara, Turkey
    Ultrasound Obstet Gynecol 27:316-9. 2006
    ..To assess whether the morphological alterations of the endometrium induced by the levonorgestrel intrauterine system affect the uterine artery vasculature...
  58. ncbi Endometrial chemokines, uterine natural killer cells and mast cells in long-term users of the levonorgestrel-releasing intrauterine system
    Alessandra Peloggia
    Human Reproduction Unit, Department of Obstetrics and Gynaecology, School of Medicine, Universidade Estadual de Campinas UNICAMP, Campinas, SP, Brazil
    Hum Reprod 21:1129-34. 2006
    ..The objective was to assess endometrial chemokines in users of the levonorgestrel-releasing intrauterine system (LNG-IUS) and correlate them with leucocyte populations, uterine natural killer cells (uNK) and mast cells (MCs)...
  59. ncbi A study of the capability of manufacturers of generic hormonal contraceptives in lower- and middle-income countries
    Peter E Hall
    Concept Foundation, Thailand Science Park, Pathumthani 12120, Thailand
    Contraception 75:311-7. 2007
    ..Studies were undertaken to assess the capability, competence and capacity of manufacturers of oral and injectable hormonal contraceptives in lower- and middle-income countries...
  60. ncbi Coexpression of fractalkine and its receptor in normal human endometrium and in endometrium from users of progestin-only contraception supports a role for fractalkine in leukocyte recruitment and endometrial remodeling
    Natalie J Hannan
    Prince Henry s Institute of Medical Research, Clayton, Victoria 3168, Australia
    J Clin Endocrinol Metab 89:6119-29. 2004
    ..These findings support a number of roles for fractalkine in the endometrium, in the secretory phase, in early pregnancy, and when influenced by progestin-only contraceptives...
  61. ncbi Undiagnosed HIV in women attending a sexual health clinic for non-barrier methods of contraception. Two case studies
    Martin Jones
    Sexual Health, Eastbourne Sexual Health Clinic, Eastbourne Downs Primary Care Trust, Eastbourne, East Sussex, UK
    J Fam Plann Reprod Health Care 29:31-2. 2003
    ..It is suggested that providers of contraception are well placed to identify clients at high risk of HIV and to recommend HIV testing...
  62. ncbi Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk
    Henry S Kahn
    Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA
    Diabetes Care 26:216-25. 2003
    ..Additional research could help clarify whether exposure to injectable or implantable contraceptives leads to increased risk of type 2 diabetes and gestational diabetes in women with predisposing factors...
  63. ncbi The local progestational effect of the levonorgestrel-releasing intrauterine system: a sonographic and Doppler flow study
    Y Zalel
    Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, Israel
    Hum Reprod 17:2878-80. 2002
    ..We aimed to evaluate the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on the uterine vasculature and the endometrium...
  64. ncbi New developments in contraception
    L M Keder
    College of Medicine, Department of Obstetrics and Gynecology, Ohio State University, Columbus, OH, USA
    J Pediatr Adolesc Gynecol 15:179-81. 2002
  65. ncbi Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers
    T Kucuk
    Department of Obstetrics and Gynecology, GATA School of Medicine, Ankara, Turkey
    Clin Exp Obstet Gynecol 35:57-60. 2008
    ..To compare the efficacy of three progestin regimens in perimenopausal menorrhagia...
  66. ncbi Clinical experience with Norplant subdermal implant system as long-term contraception during adolescence
    E Cardamakis
    Department of Obstetrics and Gynecology, University of Patras Medical School, University Hospital, Greece
    Eur J Contracept Reprod Health Care 7:36-40. 2002
    ..This study was undertaken to assess the efficacy, acceptability and side-effects of the Norplant (Leiras) contraceptive system during adolescence...
  67. ncbi Hormonal effects of Depo-Provera in cervical smears: a comparison with Triphasil and postmenopausal effects
    Stamatina Kaptain
    Department of Pathology, St Joseph s Wayne Hospital, Wayne, New Jersey, USA
    Cancer 96:74-82. 2002
    ....
  68. ncbi Recent developments in contraceptive implants at the Population Council
    Irving Sivin
    Population Council, Center for Biomedical Research, New York, NY, USA
    Contraception 65:113-9. 2002
    ..The status and rationale of studies of a new Nestorone-releasing, single implant developed by the Population Council for a period of use of 2 years are presented...
  69. ncbi Implantable contraceptives for women
    Olav Meirik
    Instituto Chileno de Medicina Reproductiva, Santiago, Chile
    Contraception 65:1-2. 2002
  70. ncbi Progestin-releasing intrauterine systems
    T Luukkainen
    Steroid Research Laboratory, Institute of Biomedicine, University of Helsinki, Helsinki, Finland
    Semin Reprod Med 19:355-63. 2001
    ..Users should be told that the LNG IUS does not prevent sexually transmitted infection, and therefore women at risk should also use condoms for their protection...
  71. ncbi Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen
    M D Kesim
    Sisli Etfal Research and Training Hospital, 3th Obstetrics and Gynecology Clinic, Istanbul, Turkey
    Climacteric 11:252-7. 2008
    ..To investigate the long-term effects of a levonorgestrel-releasing intrauterine system on the endometrium and lipid profile of breast cancer patients taking tamoxifen...
  72. ncbi [Contraception with depot gestagens]
    D Koryntová
    Gynekologicko porodnická klinika VFN a 1 LF UK, Praha
    Ceska Gynekol 66:202-8. 2001
    ..Summary of contraceptive implants and injectable contraceptives...
  73. ncbi Intrauterine contraception--what now and what next?
    J Guillebaud
    Margaret Pyke Family Planning Centre, London, UK
    Eur J Contracept Reprod Health Care 6:11-4. 2001
    ..Regarding the inconvenience of the first weeks of light post-insertion bleeding and the early-phase low incidence ofsteroidal side-effects, forewarned is forearmed!..
  74. ncbi Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis
    J B Laoag-Fernandez
    Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan
    Hum Reprod 18:694-9. 2003
    ..Endometrial angiogenesis is believed to be regulated by angiogenic factors. The study aim was to evaluate the effects of LNg-IUS on vascular endothelial growth factor (VEGF) and adrenomedullin (AM) expression in the endometrium...
  75. pmc The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphology
    V Phillips
    Department of Pathology, Royal Group of Hospitals Trust, Grosvenor Road, Belfast BT12 6BL, Northern Ireland, UK
    J Clin Pathol 56:305-7. 2003
    ..The Mirena coil is a levonorgestrel releasing intrauterine device that is in widespread use. This study aims to document the endometrial morphology associated with this device...
  76. ncbi A 5-year experience with Norplant implants in Thai women
    J Manonai
    Department of Obstetrics and Gynaecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    Int J Gynaecol Obstet 82:83-4. 2003
  77. ncbi Nondaily hormonal contraception: establishing a fit between product characteristics and patient preferences
    Jeffrey P Levine
    Departments of Family Medicine and Obstetrics, Gynecology and Reproductive Sciences, UMDNJ Robert Wood Johnson Medical School, 1 RWJ Place, CN19, New Brunswick, NJ 08903 0019, USA
    J Fam Pract 53:904-13. 2004
  78. ncbi Effect of etonogestrel subdermal contraceptive implant (Implanon) on liver function tests -- a randomized comparative study with Norplant implants
    Arijit Biswas
    Department of Obstetrics and Gynaecology, National University Hospital, National University of Singapore, 119074, Singapore
    Contraception 70:379-82. 2004
    ..The study aimed to assess the possible differences in effects of Implanon and Norplant implants on liver function over 2 years of use...
  79. ncbi Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study
    Ingrid J M Duijkers
    Dinox Medical Investigations, Groenewoudseweg 317, 6524 TX Nijmegen, The Netherlands
    Hum Reprod 19:2668-73. 2004
    ..The effects on ovarian function of the combined contraceptive vaginal ring NuvaRing and a combined oral contraceptive (COC) were compared...
  80. ncbi Conceivable sterilization: a constitutional analysis of a Norplant/Depo-Provera welfare condition
    Kimberly A Smith
    Indiana University School of Law Bloomington, USA
    Indiana Law J 77:389-418. 2002
  81. ncbi [A randomized study comparing the efficacy and bleeding pattern of Implanon and Norplant hormonal contraceptive implant]
    Xiao Ying Yao
    Department of Family Planning, Obstetric and Gynecology Hospital, Fudan University, Shanghai 200011, China
    Zhonghua Fu Chan Ke Za Zhi 38:419-22. 2003
    ..To compare the contraceptive efficacy, tolerability and bleeding patterns of Implanon and Norplant...
  82. ncbi The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study
    M Tuppurainen
    Laboratorio Gyne Oy, Kuopio, Finland
    Contraception 69:389-94. 2004
    ..These changes reflect the lower androgenicity of etonogestrel versus levonorgestrel and show that NuvaRing has a minimal effect on lipid profile...
  83. doi Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia
    Xiujuan Qi
    Department of Obstetrics and Gynecology, Qingdao University Medical School, Qingdao, PR China
    Gynecol Obstet Invest 65:266-8. 2008
    ..Histological morphology of endometrial samples after 6 months' exposure to LNG-IUS showed secretory or atrophic glands with decidualized stroma. Two healthy babies were born following ovulation induction after removal of the LNG-IUS...
  84. ncbi Current treatment of dysfunctional uterine bleeding
    Marlies Y Bongers
    Department of Obstetrics and Gynaecology, Maxima Medical Centre, P O Box 7777, 5500 MB Veldhoven, The Netherlands
    Maturitas 47:159-74. 2004
    ..We performed a review of the treatment modalities for dysfunctional uterine bleeding...
  85. ncbi Local levonorgestrel regulation of androgen receptor and 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrium
    Kevin A Burton
    Centre for Reproductive Biology, Chancellor s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
    Hum Reprod 18:2610-7. 2003
    ....
  86. ncbi The effect of a levonorgestrel-releasing intrauterine system on angiogenic growth factors in the endometrium
    B A Roopa
    Department of Obstetrics and Gynaecology, National University Hospital, National University of Singapore, Singapore
    Hum Reprod 18:1809-19. 2003
    ....
  87. ncbi Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implant
    Luis Bahamondes
    Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas, Campinas, SP, Brazil
    J Reprod Med 48:637-40. 2003
    ....
  88. ncbi Progress in contraception: new technology
    Edward S Linn
    Department of Ob Gyn, Lutheran General Hospital, Park Ridge, Illinois 60068 1174, USA
    Int J Fertil Womens Med 48:182-91. 2003
    ..This expanded menu of effective contraceptive options should help women find a method that suits their particular life style...
  89. ncbi The levonorgestrel intrauterine system: a clinical perspective from the UK
    John Guillebaud
    University College London and Margaret Pyke Centre, 73 Charlotte Street, London W1T 4PL, UK
    Ann N Y Acad Sci 997:185-93. 2003
    ..Regarding the admitted inconvenience of the first weeks of light postinsertion bleeding and the early phase low incidence of steroidal side effects: good counseling is paramount, since forewarned is forearmed!..
  90. ncbi Toxicology of polymers for implant contraceptives for women
    Prasad Venkatram Shastri
    Department of Materials Science and Engineering and School of Medicine, University of Pennsylvania and Children s Hospital of Philadelphia, Abramson Research Center, Philadelphia, PA, USA
    Contraception 65:9-13. 2002
    ..However, any future implant development using these polymers should place an emphasis on processing parameters to minimize potential small molecule leachants and establish safety as a function of both site and duration of implantation...
  91. ncbi Implanon: a new implantable contraceptive
    Yvonne G Newberry
    School of Nursing at the University of Virginia, Charlottesville, VA, USA
    Nurs Womens Health 11:607-11. 2007
  92. ncbi Combined hormonal contraception and venous thromboembolism
    Francisca Martinez
    Institut Universitari Dexeus, Barcelona, Spain
    Eur J Contracept Reprod Health Care 12:97-106. 2007
    ....
  93. doi Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial
    Mitchell D Creinin
    Department of Obstetrics, Gynecology and Reproductive Sciences and Magee Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 3180, USA
    Obstet Gynecol 111:267-77. 2008
    ..To understand if the contraceptive ring or patch was more acceptable, as measured primarily by continuation, to women using an oral contraceptive and interested in a nondaily, combined hormonal contraceptive...
  94. doi The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline
    I Mavranezouli
    National Collaborating Centre for Women s and Children s Health NCC WCH, Royal College of Obstetricians and Gynaecologists, London, UK
    Hum Reprod 23:1338-45. 2008
    ..However, their uptake is low in much of the developed world. This study aimed at assessing the cost-effectiveness of LARC methods from the British National Health Service (NHS) perspective...
  95. doi Do instructions for over-the-counter pre-coital female contraceptives promote "perfect use"?
    Nikki B Zite
    Department of Obstetrics and Gynecology, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA
    Contraception 79:211-5. 2009
    ..This study was conducted to estimate the readability and related features of English-language over-the-counter (OTC) pre-coital female contraceptive (PFC) instructions...
  96. doi Effect on carbohydrate metabolism and analysis of acceptability (menstrual cycle control) of extended regimens of the vaginally inserted hormone-releasing system 'NuvaRing' as compared with the standard 21/7 regime in reproductive-age women with type 1 di
    Elena E Grodnitskaya
    Centre of Family Planning and Reproduction of the Moscow Public Health Department, Moscow, Russia
    Gynecol Endocrinol 26:663-8. 2010
    ....
  97. ncbi The contraceptive vaginal ring
    Jill Edwardson
    Department of Gynecology and Obstetrics, Johns Hopkins Hospital, Baltimore, Maryland, USA
    Semin Reprod Med 28:133-9. 2010
    ..Serious adverse events are rare. In Chile and Peru, progesterone-only vaginal contraceptive rings are available for nursing women. Studies are ongoing examining new formulations of vaginal contraceptive rings...
  98. doi Sex education and contraceptive use at coital debut in the United States: results from Cycle 6 of the National Survey of Family Growth
    Michelle M Isley
    Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH 43210, USA
    Contraception 82:236-42. 2010
    ..The study was conducted to characterize the relationship between formal sex education and the use and type of contraceptive method used at coital debut among female adolescents...
  99. ncbi Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation: evidence-based clinical science should guide FDA decision making about product labeling
    Lee P Shulman
    Department of Obstetrics and Gynecology, Division of Reproductive Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Contraception 73:440-2. 2006
  100. ncbi Evaluating the safety of medicines, with particular reference to contraception
    D C Skegg
    Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Stat Med 20:3557-69. 2001
    ..In research on contraceptive and drug safety, conclusions usually need to be based on careful assessment of multiple observational studies...
  101. ncbi Induced abortion and unintended pregnancy in Guatemala
    Susheela Singh
    Guttmacher Institute, New York, USA
    Int Fam Plan Perspect 32:136-45. 2006
    ..Recent studies indicate that unsafe abortion is a key factor contributing to maternal morbidity and mortality in the country, but no national data on the incidence of abortion exist...

Research Grants127 found, 100 shown here

  1. INTERACTIONS BETWEEN SIMIAN AIDS (SAIDS) & LEPROSY
    Bobby Gormus; Fiscal Year: 2000
    ..L., A. Gettie, C.J. Miller and P.A. Marx. Vaginal transmission of SIV assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Research and Human Retroviruses, 13:S1-S5. ..
  2. CHEMICAL SYNTHESIS FACILITY
    Bashir Kaskar; Fiscal Year: 2012
    ..Health Branch (CRHB) supports research in the synthesis and testing of a broad spectrum of male and female contraceptive agents. Successful development of new contraceptive methods for men and women has been a goal for many decades...
  3. PROGESTERONE & ESTROGEN EFFECTS--SIV VAGINAL TRANSMISS
    Preston Marx; Fiscal Year: 1999
    ..In addition basic information will be provided on the effects of female reproductive hormones on virus transmission and viral pathogenesis. ..
  4. Control of menstrual bleeding disturbances in women
    Ian Fraser; Fiscal Year: 2002
    ..This study aims to explore these possibilities in large scale clinical studies, scientific study of vascular and molecular changes in endometrium and with the exploration of molecular mechanisms in mice. ..
  5. Control of menstrual bleeding disturbances in women
    Ian Fraser; Fiscal Year: 2006
    ..This study aims to explore these possibilities in large scale clinical studies, scientific study of vascular and molecular changes in endometrium and with the exploration of molecular mechanisms in mice. ..
  6. Control of menstrual bleeding disturbances in women
    Ian Fraser; Fiscal Year: 2004
    ..This study aims to explore these possibilities in large scale clinical studies, scientific study of vascular and molecular changes in endometrium and with the exploration of molecular mechanisms in mice. ..
  7. Control of menstrual bleeding disturbances in women
    Ian Fraser; Fiscal Year: 2003
    ..This study aims to explore these possibilities in large scale clinical studies, scientific study of vascular and molecular changes in endometrium and with the exploration of molecular mechanisms in mice. ..
  8. Control of menstrual bleeding disturbances in women
    Ian Fraser; Fiscal Year: 2005
    ..This study aims to explore these possibilities in large scale clinical studies, scientific study of vascular and molecular changes in endometrium and with the exploration of molecular mechanisms in mice. ..
  9. Depo-provera & BMD: Continuing Observations
    M Clark; Fiscal Year: 2005
    ..The longitudinal design will be continued, maintaining all methods and protocols employed in the parent study. ..
  10. DEPO-PROVERA USE AND BONE MINERAL DENSITY IN YOUNG WOMEN
    Delia Scholes; Fiscal Year: 2002
    ..The size, diversity, and range of DMPA exposure in this study group allow for comprehensive evaluation of the possibly complex association between this effective, convenient and economical contraceptive and bone mass. ..
  11. DEPO-PROVERA AND BONE DENSITY IN PREMENOPAUSAL WOMEN
    M Clark; Fiscal Year: 2002
    ..The menstrual calendar will be collected, reviewed and new calendars provided. Random coefficient regression (RCR) analysis will be the major analytic strategy. ..
  12. DEPO PROVERA AND BONE MINERAL DENSITY IN ADOLESCENTS
    Barbara Cromer; Fiscal Year: 2002
    ..The statistical analysis will estimate the effect of DMPA on bone density while taking account of constant treatment discontinuation throughout the study period. ..
  13. DEPO PROVERA AND BONE MINERAL DENSITY IN ADOLESCENTS
    Barbara Cromer; Fiscal Year: 2001
    ..The statistical analysis will estimate the effect of DMPA on bone density while taking account of constant treatment discontinuation throughout the study period. ..
  14. Oral Contraceptive Use and Bone Density in Young Women
    Delia Scholes; Fiscal Year: 2004
    ..abstract_text> ..
  15. Oral Contraceptive Use and Bone Density in Young Women
    Delia Scholes; Fiscal Year: 2007
    ..abstract_text> ..
  16. Ectopic Pregnancy: Assessing Long-Term Trends in Rates and Risk Factors
    Delia Scholes; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  17. PDE3 Inhibitors: Selective Blockers of Oocyte Maturation
    Jeffrey Jensen; Fiscal Year: 2007
    ..This approach is expected to provide a foundation for future Phase 1 trials of PDE3 inhibitors in humans. ..
  18. Depo-provera & BMD: Continuing Observations
    M Clark; Fiscal Year: 2004
    ..The longitudinal design will be continued, maintaining all methods and protocols employed in the parent study. ..
  19. DEPO PROVERA AND BONE MINERAL DENSITY IN ADOLESCENTS
    Barbara Cromer; Fiscal Year: 2002
    ..The statistical analysis will estimate the effect of DMPA on bone density while taking account of constant treatment discontinuation throughout the study period. ..
  20. PDE3 Inhibitors: Selective Blockers of Oocyte Maturation
    Jeffrey Jensen; Fiscal Year: 2006
    ..This approach is expected to provide a foundation for future Phase 1 trials of PDE3 inhibitors in humans. ..
  21. PDE3 Inhibitors: Selective Blockers of Oocyte Maturation
    Jeffrey Jensen; Fiscal Year: 2004
    ..This approach is expected to provide a foundation for future Phase 1 trials of PDE3 inhibitors in humans. ..
  22. Oral Contraceptive Use and Bone Density in Young Women
    Delia Scholes; Fiscal Year: 2005
    ..abstract_text> ..
  23. DEPO PROVERA AND BONE MINERAL DENSITY IN ADOLESCENTS
    Barbara Cromer; Fiscal Year: 2003
    ..The statistical analysis will estimate the effect of DMPA on bone density while taking account of constant treatment discontinuation throughout the study period. ..
  24. PDE3 Inhibitors: Selective Blockers of Oocyte Maturation
    Jeffrey Jensen; Fiscal Year: 2005
    ..This approach is expected to provide a foundation for future Phase 1 trials of PDE3 inhibitors in humans. ..
  25. Oral Contraceptive Use and Bone Density in Young Women
    Delia Scholes; Fiscal Year: 2006
    ..abstract_text> ..
  26. Depo-provera & BMD in Premenopausal Women: Supplement
    M Clark; Fiscal Year: 2002
    ..The menstrual calendar will be collected, reviewed and new calendars provided. Random coefficient regression (RCR) analysis will be the major analytic strategy. ..
  27. Ectopic Pregnancy: Assessing Long-Term Trends in Rates and Risk Factors
    Delia Scholes; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  28. DEPO-PROVERA AND BONE DENSITY IN PREMENOPAUSAL WOMEN
    M Clark; Fiscal Year: 2000
    ..The menstrual calendar will be collected, reviewed and new calendars provided. Random coefficient regression (RCR) analysis will be the major analytic strategy. ..
  29. Oral Contraceptive Use and Fractures Around the Menopausal Transition
    Delia Scholes; Fiscal Year: 2009
    ..Even a small increase or decrease in fracture resulting from OC use could have important implications for clinical practice and for the public health burden of fracture in women transitioning through menopause and beyond. ..
  30. DEPO-PROVERA USE AND BONE MINERAL DENSITY IN YOUNG WOMEN
    Delia Scholes; Fiscal Year: 2000
    ..The size, diversity, and range of DMPA exposure in this study group allow for comprehensive evaluation of the possibly complex association between this effective, convenient and economical contraceptive and bone mass. ..
  31. DEPO PROVERA AND BONE MINERAL DENSITY IN ADOLESCENTS
    Barbara Cromer; Fiscal Year: 2000
    ..The statistical analysis will estimate the effect of DMPA on bone density while taking account of constant treatment discontinuation throughout the study period. ..
  32. Oral Contraceptive Use and Fractures Around the Menopausal Transition
    Delia Scholes; Fiscal Year: 2008
    ..Even a small increase or decrease in fracture resulting from OC use could have important implications for clinical practice and for the public health burden of fracture in women transitioning through menopause and beyond. ..
  33. DEPO-PROVERA USE AND BONE MINERAL DENSITY IN YOUNG WOMEN
    Delia Scholes; Fiscal Year: 1999
    ..The size, diversity, and range of DMPA exposure in this study group allow for comprehensive evaluation of the possibly complex association between this effective, convenient and economical contraceptive and bone mass. ..
  34. Oral Contraceptive Use and Fractures Around the Menopausal Transition
    Delia Scholes; Fiscal Year: 2010
    ..Even a small increase or decrease in fracture resulting from OC use could have important implications for clinical practice and for the public health burden of fracture in women transitioning through menopause and beyond. ..
  35. Oral Contraceptive Use and Bone Density in Young Women
    Delia Scholes; Fiscal Year: 2008
    ..abstract_text> ..
  36. DEPO-PROVERA AND BONE DENSITY IN PREMENOPAUSAL WOMEN
    M Clark; Fiscal Year: 2001
    ..The menstrual calendar will be collected, reviewed and new calendars provided. Random coefficient regression (RCR) analysis will be the major analytic strategy. ..
  37. DEPO-PROVERA USE AND BONE MINERAL DENSITY IN YOUNG WOMEN
    Delia Scholes; Fiscal Year: 2001
    ..The size, diversity, and range of DMPA exposure in this study group allow for comprehensive evaluation of the possibly complex association between this effective, convenient and economical contraceptive and bone mass. ..
  38. DEPO-PROVERA AND BONE DENSITY IN PREMENOPAUSAL WOMEN
    M Clark; Fiscal Year: 2003
    ..The menstrual calendar will be collected, reviewed and new calendars provided. Random coefficient regression (RCR) analysis will be the major analytic strategy. ..
  39. DEPO PROVERA AND BONE MINERAL DENSITY IN ADOLESCENTS
    Barbara Cromer; Fiscal Year: 1999
    ..The statistical analysis will estimate the effect of DMPA on bone density while taking account of constant treatment discontinuation throughout the study period. ..
  40. DEPO PROVERA AND BONE MINERAL DENSITY IN ADOLESCENTS
    Barbara Cromer; Fiscal Year: 2002
    ..The statistical analysis will estimate the effect of DMPA on bone density while taking account of constant treatment discontinuation throughout the study period. ..
  41. METVAN: A Novel Anticancer Agent
    OSMOND D CRUZ; Fiscal Year: 2003
    ..The knowledge gained from these studies described under Specific Aims 1-2 is expected to facilitate the design of innovative treatment regimens employing METVAN for metastatic breast cancer and brain tumor patients. ..
  42. PHI-443: Novel Non-Spermicidal Anti-HIV Microbicide
    OSMOND D CRUZ; Fiscal Year: 2003
    ..Specific Aims 1 and 2 may provide the foundation for the clinical development of PHI-443 in Phase II studies as a safe, effective broad-spectrum anti-HIV microbicide without conception-inhibiting functions. ..
  43. The effect of nonoxynol-9 on human endometrium
    John Jain; Fiscal Year: 2005
    ..The results of this study will provide important preliminary information on the role of microbicides on endometrial toxicity and may help guide future research priorities. ..
  44. NOVEL CONTRACEPTIVES WITH ANTI-HIV ACTIVITY
    OSMOND D CRUZ; Fiscal Year: 2000
    ..The preclinical data on in vivo efficacies of WHI-05 and WHI-07 will be essential to further explore the utility of these novel drugs for clinical studies in human patients. ..
  45. Prophylactic Ibuprofen: Effect on IUD Continuation Rates
    David Hubacher; Fiscal Year: 2003
    ..In the US, ibuprofen may help spur renewed interest in the most cost effective and efficacious reversible contraceptive method available. ..
  46. Prophylactic Ibuprofen: Effect on IUD Continuation Rates
    David Hubacher; Fiscal Year: 2001
    ..In the US, ibuprofen may help spur renewed interest in the most cost effective and efficacious reversible contraceptive method available. ..
  47. Prophylactic Ibuprofen: Effect on IUD Continuation Rates
    David Hubacher; Fiscal Year: 2002
    ..In the US, ibuprofen may help spur renewed interest in the most cost effective and efficacious reversible contraceptive method available. ..
  48. Vanadocenes as a New Class of Spermicidal Drugs
    OSMOND D CRUZ; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  49. NOVEL CONTRACEPTIVES WITH ANTI-HIV ACTIVITY
    OSMOND D CRUZ; Fiscal Year: 2001
    ..The preclinical data on in vivo efficacies of WHI-05 and WHI-07 will be essential to further explore the utility of these novel drugs for clinical studies in human patients. ..
  50. FLP-102: Rationally Engineered Antiviral Protein
    OSMOND D CRUZ; Fiscal Year: 2003
    ..The preclinical data on FLP-102 will be essential to further explore the utility of this novel recombinant PAP mutant for Phase II. ..
  51. PHI 346: A Novel Dual-Function Microbicide
    OSMOND D CRUZ; Fiscal Year: 2003
    ..Following successful completion of the Phase I in vivo efficacy studies, gel formulation of PHI-346 will be further explored as a vaginal dual-function microbicide in Phase II. ..
  52. NOVEL CONTRACEPTIVES WITH ANTI-HIV ACTIVITY
    OSMOND D CRUZ; Fiscal Year: 1999
    ..The preclinical data on in vivo efficacies of WHI-05 and WHI-07 will be essential to further explore the utility of these novel drugs for clinical studies in human patients. ..
  53. Stampidine: A Novel Broad-Spectrum Anti-HIV Microbicide
    OSMOND D CRUZ; Fiscal Year: 2005
    ..Specific Aims 1 and 2 may provide the foundation for the clinical development of STAMP in Phase II studies as a safe, effective broad-spectrum anti-HIV microbicide without conception-inhibiting functions. ..
  54. Phase II SBIR: WHI-07: A Novel Dual-Function Microbicide
    OSMOND D CRUZ; Fiscal Year: 2005
    ....
  55. Mechanism for Weight Gain In Adolescents on DepoProvea
    Andrea Bonny; Fiscal Year: 2007
    ..My long-term objective with the proposed training and research plan is to become a national leader on hormonal contraception in adolescents. ..
  56. UTMB Women's Health Research Scholar's Program
    Abbey Berenson; Fiscal Year: 2008
    ..By the end of the program, all Scholars will have acquired the necessary skills to become independent, funded investigators in interdisciplinary women's health research. ..
  57. Demography Training at Princeton
    James Trussell; Fiscal Year: 2007
    ....
  58. Training in Epidemiology and Clinical Trials (TECT)
    David Grimes; Fiscal Year: 2007
    ....
  59. Improving contraceptive use/practices among young women
    Melissa Gilliam; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  60. Improving contraceptive use/practices among young women
    Melissa Gilliam; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  61. Training in Epidemiology and Clinical Trials (TECT)
    David Grimes; Fiscal Year: 2008
    ....
  62. ESTIMATING EFFICACY OF A MEDICAL INTERVENTION
    James Trussell; Fiscal Year: 1999
    ....
  63. Infrastructure for Population Research at Princeton
    James Trussell; Fiscal Year: 2007
    ..The journal Future of Children will promote effective policies and programs for children by providing policymakers, service providers, and the media with information based on the best available research. ..
  64. Infrastructure for Population Research at Princeton
    James Trussell; Fiscal Year: 2008
    ..The journal Future of Children will promote effective policies and programs for children by providing policymakers, service providers, and the media with information based on the best available research. ..
  65. Progestin Actions in the Primate Breast and Uterus
    Charles Wood; Fiscal Year: 2007
    ..This work will have immediate public health relevance to postmenopausal women seeking the safest form of hormone therapy. ..
  66. Contraceptive Services/Primary Care to Prevent Birth Defects
    Eleanor Schwarz; Fiscal Year: 2007
    ....
  67. Membrane Androgen Receptors in Neuroprotection
    Meharvan Singh; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  68. Identifying Services Changes to Improve Contraceptive U*
    Jennifer Frost; Fiscal Year: 2002
    ..By identifying gaps in knowledge and effective intervention models, it will also stimulate new research and intervention development and evaluation. ..
  69. Effect of hormonal contraception on bone mineral density
    Abbey Berenson; Fiscal Year: 2002
    ..Ultimately, this study will determine which women, if any, are placed at increased risk of osteopenia or osteoporosis as a result of using these hormonal contraceptives during their reproductive years. ..
  70. VULVODYNIA PREVALENCE AND EFFICACY OF 4 INTERVENTIONS
    Gloria Bachmann; Fiscal Year: 2002
    ..Our ultimate goal is to share findings from this and related research with the broadest cross-spectrum of women that we can. ..
  71. VULVODYNIA PREVALENCE AND EFFICACY OF 4 INTERVENTIONS
    Gloria Bachmann; Fiscal Year: 2000
    ..Our ultimate goal is to share findings from this and related research with the broadest cross-spectrum of women that we can. ..
  72. Early Environmental Hygiene and Pediatric Atopy
    Christine Johnson; Fiscal Year: 2002
    ..Further, working with Dr. F. Martinez, we will use the established repository of biospecimens to develop molecular epidemiologic studies of genetic-environmental risk factors. ..
  73. COLON CANCER SURVIVORS--MEDICATIONS & RISK OF RECURRENCE
    Christine Johnson; Fiscal Year: 2001
    ..Using automated pharmacy data, the timing of use and exposure to NSAIDs and HRT will be analyzed among cancer survivors, along with potentially confounding variables, in relation to these outcomes. ..
  74. Harnessing Health IT to Prevent Medication-Induced Birth Defects
    Eleanor Schwarz; Fiscal Year: 2007
    ..In addition, the Health IT intervention shown to be most effective will be disseminated within the University of Pittsburgh Medical Center, which provides 3 million outpatient visits each year...
  75. Increased Access to Emergency Contraceptive Pills
    Elizabeth Raymond; Fiscal Year: 2001
    ..These secondary analyses should help explain the primary biologic outcomes and should be useful in the development of counseling messages and service protocols in the future. ..
  76. Statins & Lymphoid Malignancy Risk in a Large Multi-Site Population-Based Cohort
    Marianne Ulcickas Yood; Fiscal Year: 2010
    ....
  77. A Partnership Initiative for HIV Prevention Trials
    Kathleen M MacQueen; Fiscal Year: 2010
    ..S. South. Improving the capacity for HIV prevention trials in partnership with African American communities will lay the groundwork for moving effective interventions into successful prevention programs. ..
  78. A Partnership Initiative for HIV Prevention Trials
    Kathleen Macqueen; Fiscal Year: 2009
    ..S. South. Improving the capacity for HIV prevention trials in partnership with African American communities will lay the groundwork for moving effective interventions into successful prevention programs. ..
  79. ESTIMATING EFFICACY OF A MEDICAL INTERVENTION
    James Trussell; Fiscal Year: 2000
    ....
  80. Dysregulation of IgA responses in HIV-1-infected individuals
    Zdenek Hel; Fiscal Year: 2009
    ....
  81. ESTIMATING EFFICACY OF A MEDICAL INTERVENTION
    James Trussell; Fiscal Year: 2001
    ....
  82. Demography Training at Princeton
    James Trussell; Fiscal Year: 2008
    ....
  83. The Developmental and Relationship Contexts of Sexual Abstinence Among Adolescent
    MARY OTT; Fiscal Year: 2008
    ..Upon completion, the candidate will have the skills and experience to become an independent pediatric scientist poised to advance our understanding of the role of abstinence in pregnancy and STD prevention. ..
  84. Polybrominated Biphenyls and Cancer Risk
    KARIN ROSENBLATT; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  85. Effect of hormonal contraception on bone mineral density
    Abbey Berenson; Fiscal Year: 2003
    ..Ultimately, this study will determine which women, if any, are placed at increased risk of osteopenia or osteoporosis as a result of using these hormonal contraceptives during their reproductive years. ..
  86. The Role of Prolactin in the Etiology of Postmenopausal Breast Cancer
    Shelley Tworoger; Fiscal Year: 2007
    ..This potentially may affect public health by increasing our understanding of how breast cancer develops, which in turn can lead to a better understanding of how to prevent this disease. [unreadable] [unreadable]..
  87. DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
    David Archer; Fiscal Year: 2002
    ..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..
  88. Interdisciplinary Mentoring in Women's Health
    Abbey Berenson; Fiscal Year: 2007
    ..Ultimately, this plan will allow the trainees to establish independent careers in patient-oriented research. ..
  89. Effect of hormonal contraception on bone mineral density
    Abbey Berenson; Fiscal Year: 2005
    ..Ultimately, this study will determine which women, if any, are placed at increased risk of osteopenia or osteoporosis as a result of using these hormonal contraceptives during their reproductive years. ..
  90. Mammographic Densities: In the Pathway to Breast Cancer?
    KARIN ROSENBLATT; Fiscal Year: 2005
    ..abstract_text> ..
  91. DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
    David Archer; Fiscal Year: 2005
    ..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..
  92. Contraceptive Practice /Delivery -- Community Pharmacies
    Jacqueline Gardner; Fiscal Year: 2004
    ..abstract_text> ..
  93. Identifying Services Changes to Improve Contraceptive U*
    Jennifer Frost; Fiscal Year: 2004
    ..By identifying gaps in knowledge and effective intervention models, it will also stimulate new research and intervention development and evaluation. ..
  94. Early Environmental Hygiene and Pediatric Atopy
    Christine Johnson; Fiscal Year: 2005
    ..Further, working with Dr. F. Martinez, we will use the established repository of biospecimens to develop molecular epidemiologic studies of genetic-environmental risk factors. ..
  95. Effect of hormonal contraception on bone mineral density
    Abbey Berenson; Fiscal Year: 2004
    ..Ultimately, this study will determine which women, if any, are placed at increased risk of osteopenia or osteoporosis as a result of using these hormonal contraceptives during their reproductive years. ..
  96. Early Environmental Hygiene and Pediatric Atopy
    Christine Johnson; Fiscal Year: 2004
    ..Further, working with Dr. F. Martinez, we will use the established repository of biospecimens to develop molecular epidemiologic studies of genetic-environmental risk factors. ..